Last reviewed · How we verify
Xcopri
At a glance
| Generic name | Xcopri |
|---|---|
| Sponsor | SK Life Science, Inc. |
| Target | Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Epilepsy having focal-onset seizures
- Partial seizure
Common side effects
- Somnolence
- Dizziness
- Fatigue
- Diplopia
- Headache
- Ataxia
- Nystagmus
- Vertigo
Serious adverse events
- Elevated ALT (>3x ULN)
- Elevated Potassium (>5 meq/L)
- Appendicitis
Key clinical trials
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures (PHASE3)
- Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xcopri CI brief — competitive landscape report
- Xcopri updates RSS · CI watch RSS
- SK Life Science, Inc. portfolio CI